AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Acquisitions
4
Total Acquisitions
$102.8B
Disclosed Deal Value
2024
$10.1B
AbbVie acquired ImmunoGen to add Elahere and strengthen its antibody-drug conjugate and solid tumor oncology platform.
The deal gave AbbVie a commercial ovarian cancer medicine and additional ADC pipeline expertise.
Elahere became part of AbbVie's oncology revenue mix and expanded the company's position beyond hematologic oncology.
2024
$8.7B
AbbVie acquired Cerevel to deepen its neuroscience pipeline, especially emraclidine for schizophrenia and other clinical-stage assets.
The acquisition added potential next-decade neuroscience revenue opportunities alongside Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.
Cerevel increased AbbVie's long-term neuroscience optionality, with execution depending on clinical trial and regulatory outcomes.
2020
$63.0B
AbbVie acquired Allergan to add Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets less tied to Humira.
The acquisition diversified AbbVie into aesthetics and expanded neuroscience, adding large brands and commercial channels.
Allergan became central to AbbVie's diversified post-Humira revenue base, though aesthetics demand can be more discretionary than core medicines.
2015
$21.0B
AbbVie acquired Pharmacyclics to add Imbruvica and build a stronger hematologic oncology business beyond Humira.
The deal gave AbbVie a major oncology product and helped diversify cash flow before Humira biosimilar pressure arrived.
Imbruvica became a meaningful oncology revenue contributor, though it later faced competitive pressure from newer BTK inhibitors.
AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.
AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.
AbbVie's largest acquisition was Allergan, a roughly $63 billion deal completed in 2020 that added Botox and aesthetics.
AbbVie bought Pharmacyclics in 2015 to add Imbruvica and build a stronger hematologic oncology business.
AbbVie bought ImmunoGen in 2024 to add Elahere and strengthen its solid tumor oncology portfolio.
AbbVie bought Cerevel in 2024 to deepen its neuroscience pipeline, including emraclidine for schizophrenia.
AbbVie uses acquisitions to diversify away from Humira, add late-stage pipeline assets, and expand in oncology, aesthetics, and neuroscience.